Physician profile
Jeffrey Shaw
NPI 1124083712
$2,047.16
in general payments reported to CMS, 2019-2025
17 companies · $1,077 in 2025
The $1,077 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $109 · 2022: $333 · 2023: $85.13 · 2024: $193 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $607.58 | 2022-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $507.74 | 2019-2025 | |
| Amgen INC. | $193.53 | 2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $131.63 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $117.44 | 2019-2025 | |
| Csl Behring | $110.14 | 2024-2025 | Andembry, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $67.88 | 2023-2025 | Cuvitru |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Genentech USA, INC. | $56.14 | 2023-2025 | Xolair |
| Blueprint Medicines Corporation | $52.17 | 2024 | Ayvakit |
| Glaxosmithkline, LLC. | $34.62 | 2025 | Nucala |
| Galderma Laboratories, L.P. | $23.68 | 2025 | Nemluvio |
| Lilly USA, LLC | $18.21 | 2025 | Ebglyss |
| Kaleo, INC. | $18.10 | 2023 | Auvi-Q |
| Aimmune Therapeutics, INC. | $17.00 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.44 | 2024 | |
| Incyte Corporation | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.